✦ LIBER ✦

261 POSTER Banoxantrone (AQ4N), a tissue CYP 450 targeted prodrug: the results of a Phase I study using an accelerated dose escalation in patients with advanced solid tumors

✍ Scribed by J. Sarantopoulos; A.W. Tolcher; A. Wong; G. Goel; M. Beeram; G. Lam; K. Desai; K. Woody; S. Mani; K. Papadopoulos

Book ID: 118623889
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 128 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70266-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hypoxia-Selective Targeting by the Biore

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

✍ Albertella, M. R.; Loadman, P. M.; Jones, P. H.; Phillips, R. M.; Rampling, R.; 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 694 KB

282 POSTER Preliminary results of a Phas

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

✍ P. Schöffski; H. Dumez; S.F. Jones; C. Fowst; P. Gerletti; H. Xu; J. Jakubczak; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

A phase I dose escalation study of the p

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

✍ Edwina N. Scott; Anne L. Thomas; L. Rhoda Molife; Samreen Ahmed; Sarah Blagden; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 253 KB

1468 POSTER A phase 1B, open-label, dose

1468 POSTER A phase 1B, open-label, dose-escalation study of bortezomib (Btz) in combination with gemcitabine (G) and cisplatin (C) in the first-line treatment of patients with advanced solid tumors: preliminary results

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

414 POSTER A phase I, open-label, dose e

414 POSTER A phase I, open-label, dose escalation study of the humanized monoclonal antibody (HuMAb) TRC093, an inhibitor of angiogenesis that binds to cleaved collagen, in patients with locally advanced or metastatic solid tumors

✍ M.S. Gordon; L.S. Rosen; F. Robert; D.S. Mendelson; D. Kleinzweig; B.J. Adams; C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

411 POSTER A phase I, open-label, dose-e

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

✍ R. Salgia; A. Peterson; S. Eppler; W. Yu; B. Polite; D. Geary; E. Wesolowski; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB